Cardiome Pharma Corp

Cardiome Reaches Agreement With Merck to Retire Debt and Close Line of Credit

VANCOUVER, British Columbia, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today announced that the company has reached an agreement with Merck to settle its debt obligations stemming from the companies' collaboration and license agreement for vernakalant, signed in April 2009.

Cardiome Pharma Corp

Cardiome Reports Third Quarter Results

VANCOUVER, British Columbia, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today reported financial results for the third quarter ended September 30, 2012. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP).

Cardiome Pharma Corp

NASDAQ Grants Cardiome 180 Day Extension to Regain Compliance With Bid Price Requirement

VANCOUVER, British Columbia, Oct. 31, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) announced today that the NASDAQ Listing Qualifications Staff has granted the company's request for an additional 180 day period in which to regain compliance with the minimum $1.00 bid price per share requirement.

Cardiome Pharma Corp

NASDAQ Approves Cardiome's Request to Transfer Its Listing to The NASDAQ Capital Market

VANCOUVER, Canada, Oct. 25, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (TSX:COM) (Nasdaq:CRME) announced today that the NASDAQ Listing Qualifications Staff has approved the Company's request to transfer its listing from The NASDAQ Global Market to The NASDAQ Capital Market. Accordingly, the Company's common shares will begin trading on The NASDAQ Capital Market effective with the open of business on Friday, October 26, 2012. The transfer of the Company's listing should have no impact on trading in the Company's common shares, and the Company's common shares will continue to trade under the symbol CRME. In addition, the transfer will not impact the Company's listing on the Toronto Stock Exchange.

Cardiome Pharma Corp

Cardiome to Hold Conference Call

VANCOUVER, British Columbia, Sept. 26, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today announced that a teleconference call and webcast will be held on Wednesday, September 26, 2012 at 9:00 am Eastern (6:00am Pacific) to discuss Merck's return of the global marketing and development rights for vernakalant to Cardiome.

Cardiome Pharma Corp

Merck Returns Global Marketing and Development Rights for Vernakalant to Cardiome

VANCOUVER, Canada and WHITEHOUSE STATION, N.J., Sept. 26, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Merck will return the global marketing and development rights for both the intravenous (IV) and oral formulations for vernakalant to Cardiome.

Cardiome Pharma Corp

Cardiome Announces Appointment of Jennifer Archibald as Chief Financial Officer

VANCOUVER, British Columbia, Sept. 20, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) is pleased to announce the appointment of Jennifer Archibald as Chief Financial Officer (CFO) of the company, following the resignation of Curtis Sikorsky. Mr. Sikorsky will continue to serve the company in a consulting capacity to assist during the transition.

Cardiome Pharma Corp

Cardiome Notes Updated Guidelines From European Society of Cardiology Now Include Brinavess(TM) (Vernakalant) for Infusion

VANCOUVER, B.C., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today noted that the European Society of Cardiology (ESC) has issued updated treatment guidelines for the treatment of adult patients with recent on-set atrial fibrillation, a type of irregular heartbeat. The focused update now includes the intravenous (IV) formulation of Brinavess

Cardiome Pharma Corp

Cardiome to Hold Investor Update Call

VANCOUVER, British Columbia, Aug. 21, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today announced that a teleconference call and webcast will be held on Wednesday, August 22, 2012 at 4:30 pm Eastern (1:30pm Pacific) to provide an update to the investor community.

Cardiome Pharma Corp

Cardiome Reports Second Quarter Results

VANCOUVER, British Columbia, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today reported financial results for the second quarter ended June 30, 2012. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP).